SCHEMBL2504664

SCHEMBL2504664

Nc1cc(Cl)cc(-c2cnc(C3(O)CCC3)s2)c1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.41
SMN1; SMN2 Q16637 1/20 0.32
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28821661 0.82 SYK (0.40) SYK
SCHEMBL16205268 0.81 SYK (0.41) SYK
SCHEMBL2039886 0.79 SYK (0.39) SYK
SCHEMBL2504900 0.79 SYK (0.39) SYKSMN1; SMN2
SCHEMBL16197270 0.77 SYK (0.52) SYK
SCHEMBL16197268 0.77 SYK (0.52) SYK
SCHEMBL16197266 0.77 SYK (0.52) SYK
SCHEMBL27884597 0.73 SYK (0.36) SYK
SCHEMBL23074340 0.73 SYK (0.39) SYK
SCHEMBL2042157 0.73 SYK (0.43) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243290-A1 Aminopyrimidines as SYK Inhibitors ALTMAN MICHAEL D (US) 2014-08-28 US disclosed
US-8759366-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-06-24 US disclosed
US-8551984-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-10-08 US disclosed
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2012-11-01 US disclosed
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245205-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885SMN1; SMN2 4226/4885TP53 1516/4885
US-20140243290-A1 Aminopyrimidines as SYK Inhibitors SYK, BTK, LCK SYK 1/4885SMN1; SMN2 4226/4885TP53 1516/4885
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885SMN1; SMN2 4226/4885TP53 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.